(19)
(11) EP 2 531 177 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.10.2016 Bulletin 2016/41

(45) Mention of the grant of the patent:
11.05.2016 Bulletin 2016/19

(21) Application number: 11702056.0

(22) Date of filing: 04.02.2011
(51) International Patent Classification (IPC): 
A61K 9/16(2006.01)
C07D 231/22(2006.01)
 A61K 31/4152(2006.01)
A61P 25/00(2006.01)
(86) International application number:
PCT/EP2011/051630
(87) International publication number:
WO 2011/095579 (11.08.2011 Gazette 2011/32)

(54)

4-[2-[[5-METHYL-1-(2-NAPHTHALENYL)-1H-PYRAZOL-3-YL]OXY]ETHYL]MORPHOLINE HYDROCHLORIDE POLYMORPHS AND SOLVATES

4-[2-[[5-METHYL-1-(2-NAPHTHALINYL)-1H-PYRAZOL-3-YL]OXY]ETHYL]MORPHOLIN HYDROCHLORID POLYMORPHE UND SOLVATE

POLYMORPHES D'UN SEL DE CHLORHYDRATE DE 4-[2-[[5-METHYL-1-(2-NAPHTHALENYL)-1H-PYRAZOL-3-YL]OXY]ETHYL]MORPHOLINE ET DES SOLVATES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 09.08.2010 EP 10382226
04.02.2010 EP 10382025

(43) Date of publication of application:
12.12.2012 Bulletin 2012/50

(73) Proprietor: Laboratorios del Dr. Esteve, S.A.
08041 Barcelona (ES)

(72) Inventors:
  • BERENGUER MAIMÓ, Ramón
    E-08001 Barcelona (ES)
  • MEDRANO RUPÉREZ, Jorge
    E-08921 Santa Colonia de Gramenet Barcelona (ES)
  • BENET BUCHHOLZ, Jordi
    E-43893 Altafulla - Tarragona (ES)
  • PUIG FERNANDEZ, Laura
    E-50019 Zaragoza (ES)
  • PELLEJÀ PUXEU, Laia
    E-43007 Tarragona (ES)

(74) Representative: ABG Patentes, S.L. 
Avenida de Burgos, 16D Edificio Euromor
28036 Madrid
28036 Madrid (ES)


(56) References cited: : 
EP-A1- 2 113 501
 WO-A1-2006/021462
   
  • LEE S ET AL: "Handbook of Pharmaceutical Salts: Properties, Selection , and Use, Chapter 8 (Large-Scale Aspects of Salt Formation: Processing of Intermediates and Final Products, Chapter 12 (Monographs on Acids and Bases)", 1 January 2002 (2002-01-01), HANDBOOK OF PHARMACEUTICAL SALTS : PROPERTIES, SELECTION, AND USE, ZÜRICH : VERL. HELVETICA CHIMICA ACTA ; WEINHEIM [U.A.] : WILEY-VCH, DE, PAGE(S) 191 - 192,211, XP002548973, ISBN: 978-3-906390-26-0 page 192 page 211 - page 213
  • BERGE S M ET AL: "PHARMACEUTICAL SALTS", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 66, no. 1, 1 January 1977 (1977-01-01), pages 1-19, XP002552191, ISSN: 0022-3549, DOI: DOI:10.1002/JPS.2600660104
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).